Skip to main content

Athira Pharma to Participate in Panel Discussion at Sachs 4th Annual Neuroscience Innovation Forum

Written by Customer Service on . Posted in Public Companies.

BOTHELL, Wash., April 21, 2021 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Leen Kawas, Ph.D., President and Chief Executive Officer, will participate in a virtual panel discussion at the Sachs 4th Annual Neuroscience Innovation Forum. The panel, titled “Progress in Alzheimer’s and Dementia,” will be aired on Wednesday, April 28, 2021, at 8:30 a.m. PT /11:30 a.m. ET.

The panel will be moderated by Howard Fillit, M.D., Founding Executive Director at the Alzheimer’s Drug Discovery Foundation, and Paul Matteis, Managing Director at Stifel, and will include a discussion with the following participants:

  • David Elmaleh, Ph.D., Chairman and Chief Scientific Officer, AZTherapies
  • Todd Haim, Ph.D., Chief, Office of Small Business Research, National Institute on Aging (NIH)
  • Leen Kawas, Ph.D., President and Chief Executive Officer, Athira Pharma
  • Gregor Macdonald, Ph.D., Senior Director, Neuroscience Scientific Licensing, Johnson & Johnson Innovation
  • Deborah Rathjen, Ph.D., Executive Chair, Bioasis Technologies
  • Susanne Wilke, Ph.D., President and Chief Executive Officer, Cognoptix

To register in advance for a live webcast of the panel discussion, please click here. For more information about the Sachs 4th Annual Neuroscience Innovation Forum, please refer to the conference portal.

Beginning May 26, a recording of the panel will be available on the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations. An archived replay will be available for at least 30 days.

About Athira Pharma, Inc.
Athira, headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer’s and Parkinson’s dementia. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.

Investor & Media Contact:
Julie Rathbun
Athira Pharma
Julie.rathbun@athira.com
206-769-9219

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.